Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03023644 · ClinicalTrials.gov registry record · NA

Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study

A NA study, sponsored by Boston Children's Hospital.

Completed
Registry status
NA
Development phase
106
Enrollment target

NCT03023644: Completed NA study, sponsored by Boston Children's Hospital.

NCT03023644 is a NA study that has completed, run by Boston Children's Hospital. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03023644, a NA study, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
NA
Development phase
106 participants
Enrollment target

Study Summary

Each year, approximately 1 child in every 100 is born with Congenital Heart Disease (CHD), making it the most common birth defect. With recent medical advances, more children with CHD survive early open-heart surgery, so that there are now 2 to 3 million adult survivors with CHD. These survivors face challenges in terms of their cognitive and behavioral development. For many, the limitations affect their academic achievement, social adaption and, ultimately, their quality of life. Among the most disabling limitations are those that pertain to the ability to maintain attention, plan and organize activities, regulate emotions, and develop problem-solving strategies. Collectively, these are referred to as executive functions (EF) because they are higher-order abilities that enable one to coordinate complex behaviors. Additionally, impaired EF also underlie mental health disorders. In spite of the abundance of evidence that children with CHD struggle with EF, there is little to offer them in the way of evidence-based interventions to prevent or mitigate these problems. The investigators propose to conduct the first randomized trial to evaluate the efficacy of an intervention, the Cogmed Working Memory Program, in improving the neurodevelopment outcomes of children with critical CHD after infant open-heart surgery. Children who meet eligibility criteria and who agree to participate will be randomly assigned to an intervention or control group. Children in the intervention group will complete 25 35-40 minute sessions of Cogmed training, spread over for 5 weeks. This Program is a set of home-based, child-friendly, computerized activities. The control group will receive the standard of care for children with CHD. Children's scores on EF and related neurodevelopmental tests will be evaluated before the intervention group completes Cogmed training, at the conclusion of their training, and 3 months later. The latter assessment will indicate whether any gains in EF skills of t

Primary Outcome

This standardized measure assesses the ability to process information across a series of modalities (visual-spatial and verbal), to hold this information in a short-term buffer, and to actively manipulate it mentally. It is considered an excellent composite indicator of children's executive function skills, as it requires the simultaneous implementation of control of attention and working memory abilities on tasks of increasing complexity. Mean scores are automatically computed and are compared

Interventions

  • BEHAVIORAL Cogmed Working Memory Training

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2017-02-21
Est. Completion 2020-09-30
Phase NA
Boston Children's Hospital

462 total trials

What the finished NCT03023644 record still lists

NCT03023644 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Cogmed Working Memory Training is the first listed.

NCT03023644 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03023644 about?

NCT03023644 is a clinical study titled "Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study". Each year, approximately 1 child in every 100 is born with Congenital Heart Disease (CHD), making it the most common birth defect. With recent medical advances, more children with CHD survive early open-heart surgery, so that there are now 2 to 3 million adult survivors with CHD. These survivors fac...

What is the current status of trial NCT03023644?

This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2017-02-21. Estimated completion is 2020-09-30.

What interventions are being tested in trial NCT03023644?

The interventions under investigation include: Cogmed Working Memory Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT03023644?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03023644's enrollment target sits among peer trials

106 830th of 2000 higher than 1,167 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03023644, the US trial registry maintained by the National Library of Medicine. NCT03023644 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.